A study evaluated plasma pTau217 performance in genetically admixed South American populations, aiming to expand biomarker evidence beyond populations traditionally represented in Alzheimer’s testing. The work assesses diagnostic performance for the blood-based marker that tracks a key molecular Alzheimer’s signal. By testing in a population with different ancestry composition, the dataset targets questions about generalizability of biomarker thresholds and sensitivity in real-world settings. The findings are framed as supporting broader adoption and refining diagnostic interpretation across underrepresented groups. For biotech and diagnostics developers, the result is a reminder that clinical utility claims increasingly require cross-population validation to reduce performance uncertainty when assays move into global markets.